Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

about

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

Item

http://www.wikidata.org/entity/Q58788266

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@en

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@nl

type

Item

label

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@en

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@nl

prefLabel

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@en

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@nl

P1476

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

@en

P2093

Klarissa D Jackson

http://www.w3.org/2001/XMLSchema#string

Rebecca Durandis

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib

Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants

Circumventing the Crabtree Effect: Replacing Media Glucose with Galactose Increases Susceptibility of HepG2 Cells to Mitochondrial Toxicants

Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.

P304

2367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3390/IJMS19082367

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J Vergne

P5008

ScienceSource

P577

2018-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30103502

http://www.w3.org/2001/XMLSchema#string

P921

P932

6121577

http://www.w3.org/2001/XMLSchema#string